Start free

Avalo Therapeutics, Inc. (AVTX) insider trading

Recent insider transactions reported to the SEC on Form 4 — directors and officers buying or selling their own company’s stock. Sourced directly from public SEC filings, latest filed Oct 2, 2026.

Filings shown
40
Open-market buys
0
Open-market sells
34

Counts cover the 40 most recent Form 4 filings Tradune holds for AVTX (filed May 1 – Oct 2, 2026); the score below covers only the trailing 90 days (0 buys, 3 sells). SEC EDGAR Form 4 filings for AVTX last checked Nov 21, 2026, 09:00 UTC; the latest AVTX filing Tradune holds was filed Oct 2, 2026. This is not guaranteed to be the complete record — see AVTX's full Form 4 filing history on SEC EDGAR.

Open-market activity, last 90 days

Purchases (Form 4 code P) and sales (code S) on the 6 filings Tradune holds for AVTX filed Sep 1 – Oct 2, 2026. Grants, exercises, tax withholding and the other Form 4 transaction codes are left out.

3 open-market sales by Rule 10b5-1 checkbox

On filings with the 10b5-1 box checked
3 sales· 23,258 sh
checkbox disclosed
On filings with the box not checked
0 sales· 0 sh
not proof that no plan exists
Not comparable
0 sales· 0 sh
filed before Apr 1, 2023, or no checkbox value in the filing data

Counts are Form 4 lines as filed. The checkbox is one per filing, so every sale on a filing with the box checked is counted there even if only some of its transactions were under a plan; it records what the filer disclosed, and the three categories are not a judgement about why a sale was made.

Open-market purchases and sales by insider
Insider Buys Sells Shares bought Shares sold Value
Christopher Ryan SullivanChief Financial Officer 0 2 — 22,579 −$381,894
Mittie DoyleChief Medical Officer 0 1 — 679 −$13,580

Value = shares × the price reported on each Form 4 (+ purchases, − sales); every open-market line in this window disclosed a price.

Insider-activity score

0/ 100

Net insider sales
0 distinct buyers0 buy · 3 sell tx

Summarises ~90 days of public SEC Form 4 activity — more distinct buyers, officer involvement and net buying score higher. A description of filing activity, not a rating or buy signal. How this score is computed →

Get alerted when insiders buy the stocks you own

Add your holdings — no brokerage login — and Insider Radar sends a Telegram alert when an open-market Form 4 buy of $100,000 or more is filed on a stock you hold or watch.

Free for everyone right now · no card · nothing to buy

Start free

How to read this: an open-market purchase (Form 4 code P) is a buy at the market price with the insider’s own money, as opposed to a grant, award or option exercise; an open-market sale is code S. When two or more distinct insiders report open-market purchases in the same 90-day window, this site labels that a cluster — a definition, not a forecast; see insider cluster buying. “Held after” is Form 4 Table I column 5; “Change” = shares ÷ holdings before the trade (held after − shares for an acquisition, held after + shares for a disposition).

Insider Buying at AVTX

No open-market insider purchases (Form 4 code P) were reported for AVTX between May 1, 2026 and Oct 2, 2026. The filings below may include other transaction types — sales, grants, option exercises, and tax withholding — shown for completeness; they are not open-market purchases.

Recent Form 4 filings

Source: SEC EDGAR Form 4 · transaction codes explained

Ron M. Philip Director · filed Oct 2, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 1,109 $12.29 — — Sep 30, 2026
Rita Jain Director · filed Oct 2, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 1,322 $12.29 — — Sep 30, 2026
Kevin Robert Lind Director · filed Oct 2, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 1,352 $12.29 — — Sep 30, 2026
Christopher Ryan Sullivan Chief Financial Officer · filed Sep 18, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 12,394 $9.88 52,294 +31% Sep 16, 2026
Open-market sale 10b5-1 box checked 12,394 $16.33 39,900 −24% Sep 16, 2026
Option exercise Stock Option (Right to Buy) 12,394 — — — Sep 16, 2026

† change in this filer’s own reported holding line (Form 4 Table I, col. 5), not of total company ownership; small prior holdings produce large percentages, so under 100 shares the prior holding is shown instead.

“10b5-1 box checked” = the filer checked the Form 4 box stating that a transaction on the filing was made under a plan intended to satisfy Rule 10b5-1(c); “10b5-1 box not checked” = the box was left blank, which does not prove that no plan exists. The box applies to Form 4s filed from April 1, 2023; older filings, and boxes we could not read, carry no tag. What the 10b5-1 box means.

Christopher Ryan Sullivan Chief Financial Officer · filed Sep 11, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 10,185 $8.04 50,085 +26% Sep 10, 2026
Open-market sale 10b5-1 box checked 10,185 $17.62 39,900 −20% Sep 10, 2026
Option exercise Stock Option (Right to Buy) 10,185 — — — Sep 10, 2026
Mittie Doyle Chief Medical Officer · filed Sep 1, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 679 $8.04 52,455 +1.3% Aug 28, 2026
Open-market sale 10b5-1 box checked 679 $20.00 51,776 −1.3% Aug 28, 2026
Option exercise Stock Option (Right to Buy) 679 — — — Aug 28, 2026
Christopher Ryan Sullivan Chief Financial Officer · filed Aug 19, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 31,031 $9.88 70,931 +78% Aug 18, 2026
Open-market sale 10b5-1 box checked 31,031 $20.05 39,900 −44% Aug 18, 2026
Option exercise Stock Option (Right to Buy) 31,031 — — — Aug 18, 2026
Option exercise 37,945 $9.88 78,718 +93% Aug 17, 2026
Option exercise 2,876 $9.88 81,594 +3.7% Aug 17, 2026
Open-market sale 10b5-1 box checked 37,945 $19.85 43,649 −47% Aug 17, 2026
Open-market sale 10b5-1 box checked 3,749 $19.94 39,900 −8.6% Aug 17, 2026
Option exercise Stock Option (Right to Buy) 37,945 — — — Aug 17, 2026
Option exercise Stock Option (Right to Buy) 2,876 — — — Aug 17, 2026
Mittie Doyle Chief Medical Officer · filed Aug 19, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 1,000 $12.65 52,776 +1.9% Aug 17, 2026
Open-market sale 10b5-1 box checked 1,000 $20.00 51,776 −1.9% Aug 17, 2026
Option exercise Stock Option (Right to Buy) 1,000 — — — Aug 17, 2026
Jennifer Riley Chief Strategy Officer · filed Aug 12, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 2,655 $19.59 37,041 −6.7% Aug 11, 2026
Mittie Doyle Chief Medical Officer · filed Aug 12, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 679 $8.04 52,455 +1.3% Aug 10, 2026
Open-market sale 10b5-1 box checked 679 $20.00 51,776 −1.3% Aug 10, 2026
Option exercise Stock Option (Right to Buy) 679 — — — Aug 10, 2026
Mittie Doyle Chief Medical Officer · filed Jul 29, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 1,000 $12.65 52,776 +1.9% Jul 27, 2026
Open-market sale 10b5-1 box checked 1,000 $20.00 51,776 −1.9% Jul 27, 2026
Option exercise Stock Option (Right to Buy) 1,000 — — — Jul 27, 2026
Ron M. Philip Director · filed Jul 2, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 69 $15.04 — — Jun 30, 2026
Mittie Doyle Chief Medical Officer · filed Jul 2, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 2,875 $12.65 54,651 +5.6% Jun 30, 2026
Option exercise 1,779 $8.04 56,430 +3.3% Jun 30, 2026
Open-market sale 10b5-1 box checked 4,654 $20.00 51,776 −8.2% Jun 30, 2026
Option exercise Stock Option (Right to Buy) 2,875 — — — Jun 30, 2026
Option exercise Stock Option (Right to Buy) 1,779 — — — Jun 30, 2026
Rita Jain Director · filed Jul 2, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 1,080 $15.04 — — Jun 30, 2026
Kevin Robert Lind Director · filed Jul 2, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 1,105 $15.04 — — Jun 30, 2026
Ron M. Philip Director · filed Jun 25, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 40,200 — — — Jun 23, 2026
Mittie Doyle Chief Medical Officer · filed Jun 25, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 1,450 $8.04 53,226 +2.8% Jun 23, 2026
Open-market sale 10b5-1 box checked 1,450 $18.00 51,776 −2.7% Jun 23, 2026
Option exercise Stock Option (Right to Buy) 1,450 — — — Jun 23, 2026
Jennifer Riley Chief Strategy Officer · filed Jun 12, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Tax withholding 588 $13.10 39,696 −1.5% Jun 10, 2026
Mittie Doyle Chief Medical Officer · filed Jun 12, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Tax withholding 1,084 $13.10 51,776 −2.1% Jun 10, 2026
Christopher Ryan Sullivan Chief Financial Officer · filed Jun 12, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Tax withholding 138 $13.10 40,773 −0.3% Jun 10, 2026
Paul Varki Chief Legal Officer · filed Jun 12, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Tax withholding 1,081 $13.10 32,576 −3.2% Jun 10, 2026
Samantha Truex Director · filed Jun 4, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 20,100 — — — Jun 2, 2026
Aaron Kantoff Director · filed Jun 4, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 20,100 — — — Jun 2, 2026
Rita Jain Director · filed Jun 4, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 20,100 — — — Jun 2, 2026
Kevin Robert Lind Director · filed Jun 4, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 20,100 — — — Jun 2, 2026

Listing the 25 most recent of 40 Form 4 filings held for AVTX; the 15 older filings (filed May 1 – Jun 4, 2026) are counted above but not listed here — see AVTX's full Form 4 filing history on SEC EDGAR.

Insider filings reported around the same time

Other companies whose most recent Form 4 was filed closest to AVTX's (Oct 2, 2026).

Frequently asked about AVTX insider activity

How many insiders bought AVTX stock in these Form 4 filings?

No open-market purchases (Form 4 code P) of AVTX shares were reported by Avalo Therapeutics, Inc. insiders between May 1, 2026 and Oct 2, 2026. The 40 filings shown on this page cover other transaction types — sales, grants, option exercises, and tax withholding.

Who filed the most recent Form 4 for AVTX?

The most recent Form 4 on this page was filed by Kevin Robert Lind (Director) on Oct 2, 2026, reporting 1 transaction. The original document is linked from the filing list above on SEC EDGAR. Amended filings (Form 4/A) may later revise reported figures.

What was the largest open-market AVTX insider sale shown?

The largest open-market sale among the filings shown was 44,944 AVTX shares at $21.20 (about $952,669) by Mittie Doyle (Chief Medical Officer) on May 6, 2026. Value is shares × the price reported on the Form 4; that Form 4 has the Rule 10b5-1 box checked.

New to Form 4s? The transaction codes, the 90-day window and the 0–100 score are defined on the insider-activity score methodology page.

Get insider alerts for AVTX — and your whole portfolio

Tradune watches SEC Form 4 filings and flags insider-cluster buying across everything you hold, routed to you automatically. Free for everyone right now · no card · nothing to buy

This score summarizes SEC Form 4 filing activity over the trailing 90 days. It is descriptive, not predictive — not a rating, recommendation, or investment advice. Data: SEC EDGAR (public domain), as filed; amendments may revise figures. Tradune is not a registered investment adviser.

Data as filed; amended filings (Form 4/A) may revise figures. Sales may occur under prearranged Rule 10b5-1 trading plans.